InflaRx N.V. (IFRX)
IFRX Stock Price Chart
Explore InflaRx N.V. interactive price chart. Choose custom timeframes to analyze IFRX price movements and trends.
IFRX Company Profile
Discover essential business fundamentals and corporate details for InflaRx N.V. (IFRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Nov 2017
Employees
74.00
Website
https://www.inflarx.deCEO
Niels C. Riedemann
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IFRX Financial Timeline
Browse a chronological timeline of InflaRx N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.16.
Earnings released on 7 Aug 2025
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $46.43K , beating expectations by +78.57%.
Earnings released on 7 May 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 20 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.27 by +66.67%, while revenue for the quarter reached -$438.01 , missing expectations by -100.93%.
Earnings released on 8 Nov 2024
EPS came in at -$0.33 falling short of the estimated -$0.27 by -22.22%, while revenue for the quarter reached $135.80K , beating expectations by +1.85%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%, while revenue for the quarter reached $6.84K , missing expectations by -92.41%.
Earnings released on 8 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.24 by +20.83%, while revenue for the quarter reached $38.71K , missing expectations by -97.15%.
Earnings released on 21 Mar 2024
EPS came in at -$0.30 falling short of the estimated -$0.20 by -50.00%, while revenue for the quarter reached $2.51K , missing expectations by -99.82%.
Earnings released on 1 Nov 2023
EPS came in at -$0.14 surpassing the estimated -$0.29 by +51.72%, while revenue for the quarter reached $64.14K , missing expectations by -97.02%.
Earnings released on 10 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.36 by +58.33%.
Earnings released on 11 May 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.
Earnings released on 22 Mar 2023
EPS came in at -$0.18 falling short of the estimated $0.25 by -172.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.18 surpassing the estimated -$0.36 by +50.00%.
Earnings released on 5 Aug 2022
EPS came in at $0.01 surpassing the estimated -$0.34 by +102.94%.
Earnings released on 12 May 2022
EPS came in at -$0.36 falling short of the estimated -$0.34 by -5.88%.
Earnings released on 24 Mar 2022
EPS came in at -$0.33 surpassing the estimated -$0.37 by +10.81%.
Earnings released on 5 Nov 2021
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%.
Earnings released on 5 Aug 2021
EPS came in at -$0.40 falling short of the estimated -$0.25 by -60.00%.
Earnings released on 12 May 2021
EPS came in at -$0.22 surpassing the estimated -$0.26 by +15.38%.
Earnings released on 25 Mar 2021
EPS came in at -$0.38 falling short of the estimated -$0.29 by -31.03%.
Earnings released on 29 Oct 2020
EPS came in at -$0.29 surpassing the estimated -$0.41 by +29.27%.
IFRX Stock Performance
Access detailed IFRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.